1,051
Views
13
CrossRef citations to date
0
Altmetric
Treatment Evaluation

Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus

, MD, , MD, , MD, , MD & , MD
Pages 1377-1384 | Published online: 07 Mar 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (7)

Zhongke Sun, Xuejiao Sun, Juan Li, Zhaoyang Li, Qingwei Hu, Lili Li, Xinqi Hao, Maoping Song & Chengwei Li. (2020) Using probiotics for type 2 diabetes mellitus intervention: Advances, questions, and potential. Critical Reviews in Food Science and Nutrition 60:4, pages 670-683.
Read now
André J Scheen. (2015) Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 1005-1020.
Read now
Thomas Forst & Peter Bramlage. (2014) Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Expert Opinion on Pharmacotherapy 15:9, pages 1299-1313.
Read now
Eleonora Russo, Giuseppe Penno & Stefano Del Prato. (2013) Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes, Metabolic Syndrome and Obesity 6, pages 161-170.
Read now
Niki Katsiki, Vasilios G. Athyros & Asterios Karagiannis. (2013) Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?. Journal of Drug Assessment 2:1, pages 67-71.
Read now
André J Scheen. (2013) Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. Expert Opinion on Drug Metabolism & Toxicology 9:3, pages 363-377.
Read now
André J Scheen. (2013) Efficacy and safety of Jentadueto® (linagliptin plus metformin). Expert Opinion on Drug Safety 12:2, pages 275-289.
Read now

Articles from other publishers (6)

Vikas Rathod, Pankaj Saini, Ramandeep Kaur, Srinivasa Marimganti & Kamlesh J. Ranbhan. (2023) A Critical Account of Synthetic Approaches toward Vildagliptin, an Antidiabetic Drug. Organic Process Research & Development 27:11, pages 1880-1899.
Crossref
Kumar Gautam, Ratikanta Tripathy, Dayanidhi Meher & Jyoti Prakash Sahoo. (2023) Dapagliflozin Versus Vildagliptin as an Adjuvant to Metformin in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-label Study. Cureus.
Crossref
Romeu Mendes, Nelson Sousa, José Luís Themudo-Barata & Victor Machado Reis. (2019) High-Intensity Interval Training Versus Moderate-Intensity Continuous Training in Middle-Aged and Older Patients with Type 2 Diabetes: A Randomized Controlled Crossover Trial of the Acute Effects of Treadmill Walking on Glycemic Control. International Journal of Environmental Research and Public Health 16:21, pages 4163.
Crossref
Lingli Zhou, Xiaoling Cai, Yingying Luo, Fang Zhang & Linong Ji. (2019) Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study. Journal of Diabetes Research 2019, pages 1-5.
Crossref
L.-N. Ji, C.-Y. Pan, J.-M. Lu, H. Li, D.-L. Zhu, Q. Li, Q.-F. Li, Y.-D. Peng, H.-M. Tian, C. Yao, Z.-G. Zhao, L. Wang & B.-H. Wang. (2016) Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION). Diabetes, Obesity and Metabolism 18:8, pages 775-782.
Crossref
Helena Pelantová, Martina Bugáňová, Martina Holubová, Blanka Šedivá, Jana Zemenová, David Sýkora, Petra Kaválková, Martin Haluzík, Blanka Železná, Lenka Maletínská, Jaroslav Kuneš & Marek Kuzma. (2016) Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination. Molecular and Cellular Endocrinology 431, pages 88-100.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.